Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Gross Margin (2018 - 2025)

UroGen Pharma's Gross Margin history spans 8 years, with the latest figure at 91.31% for Q4 2025.

  • For Q4 2025, Gross Margin rose 137.0% year-over-year to 91.31%; the TTM value through Dec 2025 reached 88.66%, down 151.0%, while the annual FY2025 figure was 88.66%, 151.0% down from the prior year.
  • Gross Margin reached 91.31% in Q4 2025 per URGN's latest filing, up from 88.07% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 91.31% in Q4 2025 to a low of 85.34% in Q2 2025.
  • Average Gross Margin over 5 years is 88.85%, with a median of 88.82% recorded in 2022.
  • Peak YoY movement for Gross Margin: soared 397bps in 2024, then plummeted -446bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 90.18% in 2021, then decreased by -3bps to 87.49% in 2022, then rose by 3bps to 90.28% in 2023, then decreased by 0bps to 89.94% in 2024, then rose by 2bps to 91.31% in 2025.
  • Per Business Quant, the three most recent readings for URGN's Gross Margin are 91.31% (Q4 2025), 88.07% (Q3 2025), and 85.34% (Q2 2025).